2025年全球结核病报告：信息表

TUBERCULOSISIS THE WORLD’SLEADINGINFECTIOUSKILLER TB SITUATION AND RESPONSE Tuberculosis (TB) is the world’s leading cause of death from asingle infectious agent and among the top 10 causes of deathworldwide. It was also the leading killer of people with HIV anda major cause of death related to antimicrobial resistance. TB is contagious and airborne. 1.23 MILLIONTB DEATHS INCLUDING TB BURDEN In2024,an estimated 10.7 million people fell ill with TBworldwide, including 5.8 million men, 3.7 million women and1.2 million children and young adolescents. People living withHIV accounted for 5.8% of the total.The TB incidence rate also fell, by 1.7% between 2023 and2024,and is back to the level of 2020.Globally,the netreduction in the TB incidence rate from 2015 to 2024 was 12%,farfrom the WHO End TB Strategy milestone of a 50%reduction by 2025.Globally in 2024, TB caused an estimated 1.23 million deaths,including 150 000 people with HIV, compared with 1.25 millionin 2023.In 2024, eight countries account for two thirds of the totalnumber of people who fell ill with TB: India, Indonesia, thePhilippines, China, Pakistan, Nigeria, the Democratic Republicofthe Congo and Bangladesh.The top five countriesaccounted for 55% of the global total. DEATHS AMONG PEOPLEWITH HIV150 000 TB is also the leading cause ofdeaths among people with HIVand a major contributor todeaths associated withantimicrobial resistance TB CARE AND TREATMENT Globalefforts to combat TB have saved an estimated 83million lives since 2000.Globally in 2024, 8.3 million people were reported as newlydiagnosed with TB in 2024 – a small increase from 8.2 million in2023 and 78% of the estimated number of incident cases. Ofthese, 54% were initially tested with a rapid test, up from 48% in2023.There is still a large global gap between the estimated numberof people who fell ill with TB and the number of people newlydiagnosed,withapproximately2.4millionpeoplenotdiagnosedwith the disease,or not officially reported tonational authorities in 2024. LIVES SAVED DUE TOGLOBAL EFFORTS TOCOMBAT TB83 MILLION DRUG-RESISTANT TBREMAINS A PUBLICHEALTH CRISIS Only about2 IN 5 PEOPLEwithdrug-resistantTBaccessedtreatment DRUG-RESISTANT TB Globally, an estimated 390 000 people developed multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) in 2024.A total of 164 545 people were treated for rifampicin-resistantTB (RR-TB) in 2024. This was 42% of the approximately 390 000people who developed RR-TB in 2024, almost the same as in2023.Thetreatment success rate for drug-susceptible TB remainshigh, at 88%, and has improved to 71% for RR-TB. WITH GAPS IN DETECTIONAND TREATMENT US$ 22 BILLION US$ 5.9 BILLIONWAS AVAILABLE IN 2024of which 82% domesticfinancing and US$ 1.1 billioninternational financingREQUIRED PER YEAR FORTBPREVENTION, DIAGNOSIS,TREATMENT AND CARE ADDRESSING THE CO-EPIDEMICSOF TB AND HIV Among all incident cases of TB in 2024, approximately 619 000people living with HIV developed TB, with the highest burdenoccurring in countries in the WHO African Region.The global coverage of HIV testing among people diagnosedwith TB remained high in 2024, at 82%. This was a slight increasefrom 81% in 2023 and 80% in 2022.In 2024, the global coverage of ART for people living with HIVwho were newly diagnosed with TB and reported as TB casesreached 91%, continuing the high level maintained since 2019and rising from 88% in 2023. REQUIRED PERYEAR FOR TBRESEARCH TB PREVENTIVE TREATMENTTB PREVENTIVE TREATMENT RESEARCH AND INNOVATION WHO recommends TB preventive treatment for people livingwith HIV, household contacts of those with bacteriologicallyconfirmed pulmonary TB, and clinical risk groups (e.g. thosereceiving dialysis).Globally,5.3 million people at high risk of developing TBdisease were provided with TB preventive treatment in 2024:3.5 million close contacts of people diagnosed with TB and 1.8million people living with HIV.TPT coverage was 58% among people living with HIV (up from56% in 2023) and 25% among household contacts (up from 20%in 2023). The diagnostic pipeline has expanded considerably in terms ofthe number of diagnostic classes, tests, products and methodsin development. There are new biomarker-based point-of-careandnear point-of-care test classes for the diagnosis of TBdisease, and new tests in existing diagnostic classes. In August 2025, there were 18 vaccine candidates in clinicaltrials, up from 15 in 2024: four in Phase 1, eight in Phase 2 andsix in Phase 3. They included candidates to prevent TB infectionandTB disease,and to help improve the outcomes oftreatment for TB disease.InAugust 2025,there were at least 42 clinical trials andimplementation research studies underway to evaluate drugregimens and models of delivery for TPT.At least 16 studies of novel delivery models in both communityand facility-based settings are being implemented. UPTAKE OF DIAGNOSTICS, NEWDRUGS AND REGIMENS Increasingaccess to early and accurate diagnosis using amolecul